pai1

GW-6604, an ALK5 inhibitor, exhibits clear antifibrotic effects leading to improved liver function.

Upamostat is an inhibitor of a serine protease and is a urokinase plasminogen activator (uPA) inhibitor.

Tiplaxtinin (Tiplasinin)(PAI-039) is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 of 2.7 uM.

AZ3976 is an inhibitor of PAI-1 with an IC50 of 16 μM in a plasma clot lysis assay. AZ3976 displays profibrinolytic activities.

Loureirin B can downregulate the expression of fibrosis-related molecules by regulating MMPs and TIMPs levels, inhibit scar fibroblast proliferation and suppress TGF-β1-induced fibrosis, during which TGF-β1/Smad2/3 pathway is likely involved.

TM5441 is an orally bioavailable fibrinogen activator inhibitor-1 inhibitor that inhibits several cancer cell lines with IC50 values ranging from 13.9 to 51.1 μM.It induces intrinsic cell death in several human cancer cells and attenuates Nω-nitro-1-arginine methyl ester-induced cardiac hypertension and vascular senescence.

Diaplasinin (PAI-749) is a highly efficient inhibitor of plasminogen activator inhibitor-1 (PAI-1) with antithrombotic activity. It can be used in cardiovascular disease research.

ZK824190 is an orally available and selective inhibitor of urokinase plasminogen activator (uPA), with IC50 values of 237 nM for uPA, 1600 nM for tPA, and 1850 nM for Plasmin.

Alpha 2 Antiplasmin serves as the principal circulating inhibitor of plasmin. This compound plays a crucial role in regulating fibrinolysis within blood vessels.

BT-114143 is a plasminogen activator inhibitor with an IC50 of 8.42 μM. It is applicable in research related to hemorrhagic diseases caused by excessive fibrinolysis, including traumatic bleeding, severe menorrhagia, postpartum hemorrhage, and complications of hemophilia.

GGACK (H-Glu-Gly-Arg-CMK) hydrochloride is an irreversible substrate-like inhibitor of the serine protease urokinase-type plasminogen activator (uPA).

SK-216, a specific PAI-1 inhibitor, reduces tumor angiogenesis and inhibits VEGF-induced migration and tube formation of human umbilical vein endothelial cells in vitro. This compound also alleviates bleomycin-induced pulmonary fibrosis in mice.

Bicyclic UK18 is a competitive inhibitor of human urokinase-type plasminogen activator (uPA) with a Ki value of 53 nM.

UK140 is an inhibitor of the urokinase-type plasminogen activator (uPA), with Ki values of 0.20 µM for human uPA (huPA) and 2.79 µM for mouse uPA (muPA). UK140 is applicable in studies related to tumor metastasis.

TM5275 sodium (TM5275 sodium salt) is an inhibitor of plasminogen activator inhibitor 1 (PAI-1).

Angstrom6 (A-6 peptide) is an 8 amino acid peptide derived from single chain urokinase fibrinogen activator (scuPA) that interferes with the uPA uPAR cascade and abrogates the downstream effects.Angstrom6 has antitumor activity and inhibits tumor cell migration, invasion, and metastasis by binding to CD44 and modulating CD44-mediated cell signaling.

Aleplasinin (PAZ 417) is a selective and orally active inhibitor of Plasminogen activator inhibitor-1(PAI-1) and a key negative regulator of the fibrinolytic system. Aleplasinin can be used in Alzheimer's disease studies.

UK-371804 is an effective and specific uPA inhibitor. It was selected as a candidate for further preClinicalal evaluation for the treatment of chronic dermal ulcers.

Toddalolactone ((+)-Toddalolactone) is an anti-inflammatory and analgesic.

TM5007 is a poent inhibitor of plasminogen activator inhibitor-1 (PAI-1; IC50 of 29 uM).